Stryker (NYSE:SYK) Price Target Lowered to $418.00 at Wells Fargo & Company

Stryker (NYSE:SYK) had its target price decreased by Wells Fargo & Company from $456.00 to $418.00 in a research note released on Friday,Benzinga reports. Wells Fargo & Company currently has an overweight rating on the medical technology company’s stock.

SYK has been the subject of a number of other research reports. Piper Sandler reiterated an “overweight” rating on shares of Stryker in a research note on Tuesday, January 27th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $465.00 target price on shares of Stryker in a report on Wednesday, March 4th. Evercore set a $390.00 target price on shares of Stryker in a research note on Monday, January 5th. Robert W. Baird set a $437.00 price target on Stryker in a research report on Friday, January 30th. Finally, TD Cowen downgraded Stryker from a “buy” rating to a “hold” rating and set a $387.00 price objective for the company. in a research note on Monday, January 26th. Sixteen analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $401.43.

Stryker Stock Performance

SYK traded down $19.70 during trading on Friday, hitting $295.43. 4,518,113 shares of the stock were exchanged, compared to its average volume of 1,836,681. The company has a quick ratio of 1.21, a current ratio of 1.89 and a debt-to-equity ratio of 0.66. Stryker has a 1-year low of $294.55 and a 1-year high of $404.87. The stock has a fifty day moving average price of $345.67 and a two-hundred day moving average price of $356.95. The firm has a market capitalization of $113.15 billion, a P/E ratio of 35.17, a PEG ratio of 1.84 and a beta of 0.92.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Thursday, April 30th. The medical technology company reported $2.60 earnings per share for the quarter, missing the consensus estimate of $2.98 by ($0.38). The firm had revenue of $6.02 billion during the quarter, compared to analyst estimates of $6.34 billion. Stryker had a net margin of 13.20% and a return on equity of 23.74%. Stryker’s revenue was up 2.6% compared to the same quarter last year. During the same period in the previous year, the company posted $2.84 earnings per share. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. As a group, sell-side analysts predict that Stryker will post 14.91 earnings per share for the current year.

Stryker Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Thursday, April 30th. Stockholders of record on Tuesday, March 31st were paid a $0.88 dividend. This represents a $3.52 annualized dividend and a dividend yield of 1.2%. The ex-dividend date was Tuesday, March 31st. Stryker’s dividend payout ratio (DPR) is 41.90%.

Insider Activity

In other news, Director Ronda E. Stryker sold 250,000 shares of the business’s stock in a transaction dated Wednesday, February 4th. The shares were sold at an average price of $362.92, for a total transaction of $90,730,000.00. Following the transaction, the director directly owned 2,457,331 shares in the company, valued at $891,814,566.52. The trade was a 9.23% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. 4.60% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Stryker

A number of institutional investors have recently added to or reduced their stakes in the business. Norges Bank acquired a new position in Stryker during the 4th quarter worth approximately $1,822,272,000. Auto Owners Insurance Co lifted its holdings in shares of Stryker by 35,047.0% in the 4th quarter. Auto Owners Insurance Co now owns 2,914,741 shares of the medical technology company’s stock valued at $1,024,444,000 after buying an additional 2,906,448 shares during the period. Wellington Management Group LLP boosted its stake in shares of Stryker by 22.6% in the fourth quarter. Wellington Management Group LLP now owns 6,493,276 shares of the medical technology company’s stock valued at $2,282,192,000 after buying an additional 1,198,665 shares in the last quarter. Corient Private Wealth LLC boosted its holdings in Stryker by 104.4% during the second quarter. Corient Private Wealth LLC now owns 2,245,841 shares of the medical technology company’s stock worth $887,525,000 after buying an additional 1,146,998 shares in the last quarter. Finally, Alliancebernstein L.P. lifted its position in shares of Stryker by 13.3% during the 3rd quarter. Alliancebernstein L.P. now owns 6,338,050 shares of the medical technology company’s stock valued at $2,342,987,000 after acquiring an additional 741,542 shares during the period. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Key Stryker News

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Stryker maintained its FY‑2026 outlook — $14.90–$15.10 adjusted EPS and 8%–9.5% organic sales growth — signaling management’s confidence in recovery from the cyber incident. Article Title
• Positive Sentiment: Operational cash flow and net income showed notable improvement year-over-year (operating cash flow jumped and net income rose), which supports longer‑term cash generation and capital investment. Article Title
• Neutral Sentiment: Stryker will present at the Bank of America Global Healthcare Conference on May 13 — an opportunity for management to address the cyber recovery and investor questions, but not an immediate catalyst for results. Article Title
• Negative Sentiment: Q1 results missed consensus: adjusted EPS of $2.60 vs. ~ $2.98 expected and revenue of $6.02B vs. ~$6.34B. Management cited a cyber incident that disrupted production, pressured margins and slowed growth — the primary driver of today’s selling pressure. Article Title
• Negative Sentiment: Several Wall Street firms cut Stryker price targets this morning (JPMorgan to $400, Wells Fargo to $418, Needham/BTIG lowered targets) — ratings largely remain buy/overweight but lower targets reduce near‑term upside expectations and add selling pressure. Article Title

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.